Literature DB >> 8108209

Clinical and microbiologic aspects of Staphylococcus haemolyticus infections.

D W Isaac1, T A Pearson, C A Hurwitz, C C Patrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8108209     DOI： 10.1097/00006454-199312000-00012

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


× No keyword cloud information.
  4 in total

1.  Purification and characterization of recombinant Staphylococcus haemolyticus DNA gyrase and topoisomerase IV expressed in Escherichia coli.

Authors:  Joel C Bronstein; Stacey L Olson; Kristin LeVier; Mark Tomilo; Peter C Weber
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

Review 2.  Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children.

Authors:  K A Rodvold; J A Everett; R D Pryka; D M Kraus
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

3.  Significance of methicillin-teicoplanin resistant Staphylococcus haemolyticus in bloodstream infections in patients of the Semmelweis University hospitals in Hungary.

Authors:  K Kristóf; E Kocsis; D Szabó; S Kardos; V Cser; K Nagy; P Hermann; F Rozgonyi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-11       Impact factor: 3.267

4.  Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of Staphylococcus warneri.

Authors:  Kimberly J Center; Annette C Reboli; Robin Hubler; Gail L Rodgers; Sarah S Long
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.